Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

George Adams

Interventional Cardiology Garner, NC Medical Doctor

NPI 1962504100 CMS profile 133883

400 Health Park Dr Ste 120, Garner, NC 27529

Open in the dashboard

General payments

$4,149,480

745 records reported · program years 2019–2025

Research payments

$143,950

Paid to them · 5 records reported · program years 2019–2025

Ownership & investment interest

$4,084

2 holdings reported · through program year 2025

Research they led as principal investigator

$1,085,612 paid to institutions, not to them · program years 2019–2025

Through program year 2025, George Adams of Garner, NC is reported in the CMS Open Payments database as having received $4,149,480 across 745 general payments and $143,950 in research payments paid to them. Separately, studies naming them as principal investigator received $1,085,612 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $4,084 across 2 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $704,026 86
2024 General $920,615 99
2023 General $655,112 92
2022 General $589,850 77
2021 General $799,394 115
2020 General $175,070 84
2020 Research $15,975 2
2019 General $305,415 192
2019 Research $127,975 3
2020 Ownership $1 1
2019 Ownership $4,083 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • George Adams
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to George Adams were reported at $704,026. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year George Adams Interventional Cardiology median Middle half National median
2019 $305,415 $1,097 $329–$3,048 $163
2020 $175,070 $473 $161–$1,480 $114
2021 $799,394 $677 $233–$1,827 $132
2022 $589,850 $978 $333–$2,724 $149
2023 $655,112 $1,136 $382–$2,986 $160
2024 $920,615 $1,181 $395–$3,326 $164
2025 $704,026 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Cordis US Corp. $2,502,829 73 payments
  2. Boston Scientific Corporation $651,080 30 payments
  3. Shockwave Medical, Inc $441,856 141 payments
  4. Abbott Laboratories $132,011 134 payments
  5. Cardiovascular Systems Inc. $118,691 64 payments
  6. Cook Incorporated $89,300 13 payments
  7. W. L. Gore & Associates, Inc. $55,509 53 payments
  8. Philips Electronics North America Corporation $45,491 41 payments
  9. Bard Peripheral Vascular, Inc. $18,575 7 payments
  10. Asahi Intecc USA, Inc. $13,586 18 payments
  11. Other $80,551 171 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $2,996,962 178 payments
  2. Acquisitions $645,159 3 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $216,855 32 payments
  4. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $79,060 17 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $69,610 12 payments
  6. Honoraria $68,124 24 payments
  7. Travel and Lodging $31,202 43 payments
  8. Food and Beverage $24,508 433 payments
  9. Long term medical supply or device loan $11,000 2 payments
  10. Education $7,000 1 payment
Products named General payments · program years 2019–2025
  1. GENERAL THERAPIES $619,323 1 payment
  2. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Lithoplasty $225,272 77 payments
  3. Vascular Lithotripsy Lithoplasty $124,319 31 payments
  4. Peripheral Orbital Atherectomy System $101,120 44 payments
  5. Omnilink Elite vascular stent system Vascular $59,750 14 payments
  6. Omnilink Elite vascular stent system Vascular $49,950 11 payments
  7. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Cardiology $49,420 17 payments
  8. Zilver PTX $48,463 20 payments
  9. Product in Development $46,931 29 payments
  10. Vascular Lithotripsy Lithoplasty $42,845 16 payments
  11. Other $247,607 424 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Philips Electronics North America Corporation $130,450 4 payments
  2. DeVoro Medical Inc. $13,500 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

2,427

Median for Cardiology: 2,533

Drug cost

$396,002

Median for Cardiology: $485,213

Branded share of claims

38.7%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 273 $260,156
Xarelto Rivaroxaban Brand 55 $56,947
Repatha Sureclick Evolocumab Brand 46 $42,303
Praluent Pen Alirocumab Brand 18 $13,215
Clopidogrel Clopidogrel Bisulfate Brand 424 $4,194
Metoprolol Succinate Generic 200 $2,146
Atorvastatin Calcium Generic 214 $1,601
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 85 $1,328
Losartan Potassium Generic 102 $1,323
Ranolazine Er Ranolazine Brand 22 $1,142

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 99 billing codes

Paid by Medicare

$505,335

Of which drugs: $1,859

Medicare patients

778

Average age 76

Services billed

2,801

354 women, 424 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 57%
Arthritis 51%
Diabetes 35%
Chronic kidney disease 32%
Atrial fibrillation 30%
Heart failure 29%
Cancer 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 55 220 $1,027
Injection, perflutren lipid microspheres, per ml Q9957 Office 12 24 $793

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $20
$20 — —
ELIQUIS
  • PFIZER INC. $17
$17 273 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

750 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record